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Antisense (AS) peptides complementary to the b-bulge surface loopVQGEESNDK (Boraschi loop) of the
cytokine interleukin-1b (IL-1b) have been shown to bind IL-1b at the Boraschi loop position, and to
inhibit some of the IL-1b-mediated biological effects in vitro. Here we show that primary AS peptide
FVITFFSLY inhibits IL-1b-mediated immunostimulation in vivo in a dose-dependent fashion, while
inactive on IL-1b-induced inﬂammation, an effect that takes place independently of theBoraschi loop.
To the best of our knowledge, this is the ﬁrst time that anASpeptide has beenused successfully in vivo.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction sults from translating the complementary nucleotide sequence ofInterleukin 1b (IL-1b) is a potent inﬂammatory and immuno-
stimulatory cytokine involved in the ﬁrst steps of the host response
to invasion [1]. Deranged regulation of IL-1 underlies the patholog-
ical symptoms of several chronic inﬂammatory and autoimmune
diseases such as rheumatoid arthritis. IL-1b is active through inter-
action with a speciﬁc receptor complex on the cell surface, encom-
passing the ligand-binding chain IL-1RI and the accessory chain IL-
1RAcP. Another receptor (IL-1RII) binds IL-1b with non-signalling
decoy function [2].
A nine amino acid-long peptide (VQGEESNDK), corresponding to
the exposed b-bulge in position 163–171 (47–55 mature sequence)
between the fourth and the ﬁfth b-strand of the IL-1b structure (Bor-
aschi loop), canmimic the immunostimulatory effects of IL-1b in vivo
being devoid of inﬂammatory effects [3]. To better understand the
role of the Boraschi loop in the IL-1b structure-function relationship,
several experimental approaches have been undertaken, involving
speciﬁc antibodies and synthetic peptides [4–7]. Here we report a
new approach that makes use of speciﬁc interactions between sense
(S) peptides and corresponding antisense (AS) peptides [8–10].
A sense (S) peptide is that encoded by the nucleotide sequence
(50 to 30) of a given ORF in sense (+) strand DNA. The AS peptide re-chemical Societies. Published by E
leukin-1b; IL-1a, interleukin-
nterleukin-1 receptor.
chi).the corresponding AS () DNA strand. Synthetic AS peptides specif-
ically interact with S peptides, bind to complementary S peptide re-
gions in proteins, and inhibits protein activities [8–10]. To explain
this interaction, the theory of inter-peptide pair-wise amino acid
interactions (M–I pair theory) gives rise to the concept of the pro-
teomic code, according to which the genetic code also has the
embedded capacity to code for through-space interactions between
amino acid residues thereby helping to deﬁne the three-dimen-
sional structures of polypeptides and protein/protein interactions.
Best characterised among AS peptides are those against IL-1b
[11], in particular those designed on the IL-1b Boraschi loop [12–
14]. The AS peptides of the Boraschi loop can bind to the corre-
sponding S peptide and to the entire IL-1b and inhibit some of its
biological activities. Inhibition was demonstrated only in vitro
[12–14]. Here we demonstrate the inhibitory properties of anti-
IL-1b AS peptides in vivo, and exploit the AS speciﬁcity of
recognition to examine the relevance of the Boraschi loop for the
multifaceted functions of IL-1b.2. Materials and methods
2.1. Animals and cells
C3H/HeJ femalemice (The Jackson Laboratory, BarHarbor,ME) of
7–11 weeks of age were used. Themurine thymoma EL4-6.1 (ATCC;
Rockville, MD) and the RAJI clone 1H7 [15] were maintained inlsevier B.V. All rights reserved.
Table 1
Sequence of primary and secondary Antisense (AS) peptides of the interleukin-1b (IL-
1b) b-bulge in position 163–171 (Boraschi loop).
Description Sequence
Boraschi loop peptide Val Gln Gly Glu Glu Ser Asn Aps Lys
DNA sequence (50–30) GTA CAG GGA GAA GAA AGT AAT GAC AAA
Reverse DNA sequence (30–50) AAA CAG TAA TGA AAG AAG AGG GAC ATG
Complementary mRNA (50–30) UUU GUC AUU ACU UUC UUC UCC CUG UAC
D. Boraschi et al. / FEBS Letters 583 (2009) 792–796 793culture medium (RPMI-1640; Gibco-Europe, Paisley, Scotland; con-
taining 2 mM L-glutamine, 25 mMHEPES buffer, and 50 lg/ml gen-
tamicin sulfate; Sigma Chemical Co., St. Louis, MO) supplemented
with10%heat-inactivated FBS (HyClone, Sterile Systems, Logan,UT).
2.2. Reagents
Synthetic peptides VQGEESNDK, LKDDKPTLQ, FVITFFSLY,
FVVGLLTVD, and FVVGLLTVK were synthesized in solid-phase,
puriﬁed and prepared as HCl salts as described [3]. Human recom-
binant IL-1b was expressed in Escherichia coli and puriﬁed to
homogeneity [3]. Sheep red blood cells (SRBC) were obtained from
Sclavo (Siena, Italy). Puriﬁed pneumococcal polysaccharide type III
(SIII) was kindly provided by Phillip J. Baker (National Institute of
Allergy and Infectious Diseases, Bethesda, MD). All reagents were
endotoxin-free as determined by the LAL assay (QLC-1000; Bio
Whittaker, Walkersville, MD).
2.3. In vivo immunostimulation
Determination of speciﬁc antibody-producing cells (PFC) in the
spleen was performed as previously described [3,16]. Brieﬂy, mice
were administered the antigen (SRBC; 1–2  108/mouse i.v.; or SIII,
2.5 lg/mouse i.p.) and, at the same time, the adjuvants i.p.: IL-1b
(150 pg/kg), the Boraschi loop peptide 163–171, or the 189–197
peptide LKDDKPTLQ (both 1 ng/kg) alone or admixed with AS pep-
tides. The number of speciﬁc splenic PFC was determined after 4 d
(for SRBC) or 5 d (for SIII) by the Cunningham and Szenberg slide
technique.
2.4. Neutrophilia
Mice (3/group) received 100 ll endotoxin-free sterile saline i.v.
containing 100 ng IL-1b, 10 lg of the Boraschi loop peptide 163–
171 or of the primary AS peptide, or IL-1b admixed with peptides.
After 90 min, blood was collected and total leukocytes counted on
cytocentrifuge smears and cytoﬂuorimetrically (FACScan, Becton-
Dickinson, Mountain View, CA).
2.5. Receptor binding assay
Cells expressing IL-1RI (EL4-6.1) or IL-1RII (1H7) were used
[15]. Cells (1  106/tube) were incubated with 0.3 nM 125I-labelled
ligands IL-1a (DuPont-NEN, Bad Homburg, Germany), IL-1b, or
peptide VQGEESNDK-Y (both radiolabelled as described [4,15])
alone or admixed with AS peptides. Incubations were carried out
for 90 min at room temperature for IL-1a and IL-1b, and for
120 min at 37 C for the peptide 163–171 under gentle agitation.
Non-speciﬁc binding was determined by adding a 1000-fold molar
excess of unlabelled ligand. Cell-bound radioactivity was counted
in a gamma counter (Packard, Downers Grove, IL).
2.6. Statistical analysis
Duplicate–quadruplicate determinations were performed for
each experimental group in each experiment. Experiments were
repeated 2–8 times. Data reported are mean ± S.E.M. of replicate
experiments or of replicate determinations within single represen-
tative experiments. Statistical signiﬁcance was assessed by Stu-
dent’s t-test.Primary AS peptide Phe Val Ile Thr Phe Phe Ser Leu Tyr
Secondary AS peptide A Phe Val Val Gly Leu Leu Thr Val Asp
Secondary AS peptide B Phe Val Val Gly Leu Leu Thr Val Lys
Molecular weights of the AS peptides: primary AS peptide FVITFFSLY, 1136.36;
secondary AS-A peptide FVVGLLTVD, 962.27; secondary AS-B peptide FVVGLLTVK,
975.36.3. Results
The primary AS peptide sequence was deduced from the Bora-
schi loop DNA sequence (Table 1). Sequences of two secondaryAS peptides were obtained by systematically replacing amino acids
with alternative residues according to the M–I pair rules (Fig. 1A).
AS peptide optimisation based on the hydropathy–hydrophilicity
approach [11] yielded identical results (Fig. 1B). Peptides, synthe-
sized and puriﬁed as described [3], are listed in Table 1.
IL-1b and its Boraschi loop peptide are potent adjuvants for
in vivo T-dependent responses such as that to SRBC [3,16]
(Fig. 2A). The synthetic peptide corresponding to the IL-1b loop
in positions 189–197 (LKDDKPTLQ) also has adjuvant activity
(Fig. 2A). The primary AS peptide inhibited immunostimulation
by IL-1b or the Boraschi loop peptide, with 50% inhibition achieved
at AS/adjuvant molar ratio 100:1 for IL-1b, and 1:1 for the Boraschi
loop peptide (Fig. 2A). By contrast, adjuvanticity of the 189–197
peptide is not affected, consistent with the speciﬁcity of the AS
peptide for the Boraschi loop S sequence. The AS peptide can also
inhibit adjuvanticity of both IL-1b and the Boraschi loop peptide
(but not the 189–197 peptide) for the T helper-independent im-
mune response against the pneumococcal SIII polysaccharide
(Fig. 2B). In this case, the immunostimulatory effects of both adju-
vants were inhibited to the same extent, with 50% inhibition at a
molar ratio of about 200:1 (Fig. 2B).
In a preliminary set of experiments, the two secondary AS pep-
tides proved slightly more effective IL-1b inhibitors than the pri-
mary AS peptide, as far as the response to SRBC is concerned. For
the secondary AS peptide AS-B, inhibition of IL-1b immunostimu-
lation was improved by about 10-fold, as compared to the primary
AS peptide, with 50% inhibition achieved at 10:1 ratio (Fig. 2A). For
the secondary AS peptide AS-A, inhibition of IL-1b immunostimu-
lation was similar in potency to that obtained with the primary
AS peptide, although inhibition of the Boraschi loop peptide effect
was increased and comparable to that by the secondary AS-B pep-
tide (data not shown).
To assess the role of the Boraschi loop in the IL-1b inﬂammatory
effects, IL-1b-induced neutrophilia was measured, an early event in
the inﬂammatory response to infection/injury. Neutrophilia is in-
duced in the mouse by IL-1b at doses signiﬁcantly higher than
those required for immunostimulation, whereas the Boraschi loop
peptide 163–171 is inactive even at high doses (Fig. 2C). Likewise,
the primary AS peptide has no effect in the same assay. Considering
the afﬁnity of the primary AS peptide for IL-1b (17 lM) [14] and
the higher absolute quantity of cytokine, the AS peptide was ad-
mixed with IL-1b at a molar ratio of over 1500:1, largely exceeding
that required for inhibiting immunostimulation. Even under such
conditions, the primary AS peptide did not show any inhibition
of IL-1b-induced neutrophilia (Fig. 2C). As a control, IL-1b was ad-
mixed with the Boraschi loop peptide at the same ratio, again with-
out any signiﬁcant effect on IL-1b-induced neutrophilia.
To evaluate whether the AS peptides inhibited IL-1b activities
by interfering with its binding to cognate receptors, two cell lines
expressing either IL-1RI or IL-1RII were used (Table 2). Primary and
Fig. 1. M–I pair theory diagram and hydropathy plot of the Boraschi loop peptide against primary and secondary Antisense (AS) peptides. (A) Schematic representation of
Mekler-Idlis (M–I) amino acid pairs. Pairs of related amino acids are connected by solid lines. Three discrete groups of M–I pairings are deﬁned as Group I (or b), Group II (or
a), and Group III (or s). Nonpolar residues are in black, polar residues are in grey. Stop indicates a stop codon. Adapted from [9] with permission. (B) The averaged hydropathic
proﬁle of the Boraschi loop peptide 163–171 of interleukin-1b (IL-1b) (d) is compared to those of its complementary peptides, the primary AS peptide (AS; s), and the
secondary AS peptides AS-A (4) and AS-B (r). Hydropathy values were determined by assigning to each amino acid a hydropathic value based on the Kyle & Doolittle scale
[17].
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Fig. 2. Effect of AS peptides on the in vivo biological activities of IL-1b and of the Boraschi loop peptide 163–171. (A) Speciﬁc PFC were counted in the spleen of mice
immunised with the T-dependent antigen SRBC together with saline ( ) or one of the following adjuvants: IL-1b (150 pg/kg; h), the Boraschi loop 163–171 peptide (1 ng/kg;
j), or the 189–197 loop peptide (1 ng/kg; ). IL-1b and peptide adjuvants were administered alone, or admixed at different ratios with the primary AS peptide FVITFFSLY (IL-
1b + AS,s; 163–171 + AS;d; 189–197 + AS, ) or with the secondary AS-B peptide (IL-1b + AS-B,r; 163–171 + AS-B;.). Data are from 8 experiments, each including 3 mice/
group. Mean background anti-SRBC PFC/spleen were 34038 ± 1595. S.E.M were less than 10% (not shown). (B) Speciﬁc PFC were measured in the spleen mice immunised with
the T-helper-independent antigen SIII together with adjuvants alone (IL-1b, h; 163–171, j; 189–197, ) or admixed with the primary AS peptide (IL-1b + AS, s; 163–
171 + AS, d; 189–197 + AS, ). Data from 3 replicate experiments are expressed as percent of the adjuvant effect. The adjuvant effect (adjuvant-induced PFC/spleen above
those induced by SIII alone) was: IL-1b 1613 PFC/spleen; Boraschi loop peptide 163–171: 3960 PFC/spleen; 189–197 peptide: 1639 PFC/spleen. Mean background PFC/spleen
(in response to SIII without adjuvant) was 1819. S.E.M were less than 10% (not shown). C: Neutrophilia in mice was measured as number of circulating PMN 90 min after
inoculum of saline ( ), the primary AS peptide (h), or the 163–171 peptide (j), either alone (left columns), or together with IL-1b (right columns).
794 D. Boraschi et al. / FEBS Letters 583 (2009) 792–796secondary AS peptides did not inhibit binding of IL-1b to either IL-
1RI or IL-1RII, as compared to the control ligand IL-1a, consistent
with the hypothesis that the Boraschi loop is not involved in
binding of IL-1b to IL-1RI. By contrast, AS peptides apparently inhi-
bit association of the Boraschi loop peptide to cells (an IL-1R-inde-
pendent event [4]), most probably due to ‘‘cold ligand” dilution
effect.4. Discussion
The exposed Boraschi loop (VQGEESNDK; position 163–171 in
the IL-1b sequence) can selectively reproduce the immunostimula-
tory properties of IL-1b while exhibiting no inﬂammatory activity
[3,16]. Cell activation is initiated upon binding of IL-1b to its recep-
tor IL-1RI. From studies with synthetic peptides, antibodies and
Table 2
Effect of AS peptides on IL-1 or Boraschi loop peptide binding to IL-1RI and IL-1RII.
Cells Peptide Percent binding of
IL-1a IL-1b Pep 163–171
EL4-6.1 (IL-1RI+)
None 100.0 100.0 100.0
Primary AS 97.0 103.8 63.1
Secondary AS-A 88.6 88.2 75.9
Secondary AS-B 92.4 121.8 88.1
1H7 (IL-1RII+)
None 100.0 100.0 100.0
Primary AS 147.4 109.4 48.0*
Secondary AS-A 91.2 82.6 56.6*
Secondary AS-B 83.7 86.2 57.0*
Results are the mean of data from 2–7 separate assays and are expressed as per-
centage of speciﬁc binding in the absence of AS peptides. AS peptides (see Table 1)
were incubated for 30 min at room temperature with the 125I-labelled ligand (IL-1a,
IL-1b, or the Boraschi loop peptide 163–171) before addition to cells. Data reported
were obtained with the highest ratios (AS peptide to radiolabelled ligand) used:
106:1 (for IL-1a), 200000:1 (for IL-1b), and 1000:1 (for peptide 163–171). No sig-
niﬁcant effects were seen at lower ratios (not shown). Binding was performed for
90 min at room temperature for IL-1a and IL-1b, and for 120 min at 37 C for the
peptide 163–171. Mean speciﬁc binding on EL4-6.1 (indicated as 100% in the table)
was: IL-1a, 5749 ± 1257 cpm; IL-1b 2370 ± 413 cpm; 163–171 peptide,
3975 ± 2574 cpm. Mean speciﬁc binding on 1H7 (indicated as 100% in the table)
was: IL-1a, 2508 ± 307 cpm; IL-1b, 3197 ± 1346 cpm; 163–171 peptide,
4827 ± 1142 cpm. *P < 0.05.
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rect contact with IL-1RI, as also evident in the crystal structure of
the IL-1b/IL-1RI complex [4,6,7,18–21]. Thus, immunostimulation
by the Boraschi loop may occur after the initial binding of IL-1b
to IL-1RI, e.g. by triggering post-receptor intracellular pathways
following ligand internalisation.
The present results indicate that AS peptides speciﬁcally inhibit
immunostimulation by IL-1b but do not inhibit inﬂammation-re-
lated effects of IL-1b in vivo, consistent with a discrete role for
the Boraschi loop in IL-1b immunostimulation. These in vivo data
are also consistent with previous in vitro data showing the speciﬁc
interactions between AS peptides and the corresponding Boraschi
loop in IL-1b [12–14]. Receptor binding data (Table 2) are also con-
sistent with the notion that IL-1b interaction with IL-1RI does not
involve the Boraschi loop directly, since it cannot be obviously re-
duced by the presence of AS peptides. The fact that Boraschi loop
peptide association to cells is decreased in the presence of high
concentrations of AS peptides in particular on cells which do not
bear IL-1RI (Table 2) is again consistent with evidence of the Bor-
aschi loop activity being independent of IL-1b interaction with
IL-1RI. This further supports the hypothesis of a post-receptor
intracellular action. After receptor-mediated entry of IL-1b and
its fragmentation, the Boraschi loop peptide may translocate to
the nucleus and bind to DNA, as it has been shown for the corre-
sponding synthetic peptide [4] (Boraschi, unpublished), possibly
acting as a transcriptional regulator. That IL-1b may have multiple
activities, both receptor-mediated and as cytoplasmic or nuclear
factor, is a notion already suggested by experimental evidence
[4,22–24]. The present data with AS peptides indicate that this
may indeed be the case.
Overall, the data reported here should be seen as a signiﬁcant
demonstration of the selective use of AS peptides in vivo, and rep-
resent an important development of previous evidence of selective
inhibition of IL-1b effects in vitro by AS peptides [12–14]. We be-
lieve that the potential utility of AS peptides as drug discovery
leads or even as drugs in their own right, for the inhibition of pro-
tein-protein interactions for therapeutic beneﬁt, should now be
fully contemplated.Acknowledgements
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